BioCentury
ARTICLE | Clinical News

Angeliq drospirenone/estradiol regulatory update

March 12, 2012 7:00 AM UTC

FDA approved a 0.25 mg/0.5 mg dose of Angeliq drospirenone/estradiol to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus. Bayer already markets 0.5 mg/1 mg drosp...